MBRX
Moleculin Biotech, Inc.
Biotechnology
Market Cap$29M
5Y Perf.-97.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
MBRX vs AGIO vs IMVT vs CRL
Revenue, margins, valuation, and 5-year total return — side by side.
AGIO
Agios Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.64B
5Y Perf.-46.8%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+6.1%
CRL
Charles River Laboratories International, Inc.
Medical - Diagnostics & Research
Market Cap$8.98B
5Y Perf.+1.3%
MBRX vs AGIO vs IMVT vs CRL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MBRX | AGIO | IMVT | CRL |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $29M | $1.64B | $5.53B | $8.98B |
| Revenue (TTM) | $0.00 | $66M | $0.00 | $4.03B |
| Net Income (TTM) | $-24M | $-423M | $-464M | $-185M |
| Gross Margin | — | 82.1% | — | 24.9% |
| Operating Margin | — | -7.2% | — | 11.8% |
| Forward P/E | — | — | — | 16.4x |
| Total Debt | $222K | $62M | $98K | $3.07B |
| Cash & Equiv. | $9M | $89M | $714M | $214M |
MBRX vs AGIO vs IMVT vs CRL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MBRX
AGIO
IMVT
CRL
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Moleculin Biotech, … (MBRX) | 100 | 2.5 | -97.5% |
| Agios Pharmaceutica… (AGIO) | 100 | 53.2 | -46.8% |
| Immunovant, Inc. (IMVT) | 100 | 106.1 | +6.1% |
| Charles River Labor… (CRL) | 100 | 101.3 | +1.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MBRX vs AGIO vs IMVT vs CRL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MBRX and AGIO are tied at the top with 2 categories each — the right choice depends on your priorities. Agios Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. IMVT and CRL also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
MBRX
Moleculin Biotech, Inc.
The Income Pick
MBRX carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 1 yrs, beta 1.22, yield 0.4%
- 0.4% yield; 1-year raise streak; the other 3 pay no meaningful dividend
- +149.2% vs AGIO's -2.4%
Best for: income & stability
AGIO
Agios Pharmaceuticals, Inc.
The Growth Play
AGIO is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 48.0%, EPS growth -161.2%, 3Y rev CAGR 56.0%
- Lower volatility, beta 1.12, Low D/E 5.2%, current ratio 11.46x
- Beta 1.12, current ratio 11.46x
- 48.0% revenue growth vs IMVT's -21.3%
Best for: growth exposure and sleep-well-at-night
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 173.6% 10Y total return vs CRL's 119.2%
- 3.2% margin vs AGIO's -6.4%
Best for: long-term compounding
CRL
Charles River Laboratories International, Inc.
The Niche Pick
CRL is the clearest fit if your priority is efficiency.
- -2.5% ROA vs MBRX's -112.5%, ROIC 6.3% vs -441.5%
Best for: efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AGIO | 48.0% revenue growth vs IMVT's -21.3% |
| Quality / Margins | IMVT | 3.2% margin vs AGIO's -6.4% |
| Stability / Safety | AGIO | Beta 1.12 vs CRL's 1.52, lower leverage |
| Dividends | MBRX | 0.4% yield; 1-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | MBRX | +149.2% vs AGIO's -2.4% |
| Efficiency (ROA) | CRL | -2.5% ROA vs MBRX's -112.5%, ROIC 6.3% vs -441.5% |
MBRX vs AGIO vs IMVT vs CRL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
Segment breakdown not available.
FY 2025
MBRX vs AGIO vs IMVT vs CRL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCRLLAGGINGAGIO
Who Leads Where
CRL leads in 3 of 6 categories
IMVT leads 1 • MBRX leads 0 • AGIO leads 0 • 1 tied
Explore the data ↓AGIOAgios Pharmaceuticals…
0leads
MBRXMoleculin Biotech, In…
0leads
IMVTImmunovant, Inc.
1leads
CRLCharles River Laborat…
3leads
6 Total Categories
CATEGORYLEADERvs IMVTvs MBRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CRL3/6
Valuation MetricsMultiples, price ratios, and targets
CRL2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CRL5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CRL leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CRL and IMVT operate at a comparable scale, with $4.0B and $0 in trailing revenue. Profitability is closely matched — net margins range from -4.6% (CRL) to -6.4% (AGIO). On growth, AGIO holds the edge at +137.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MBRXMoleculin Biotech… | AGIOAgios Pharmaceuti… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $66M | $0 | $4.0B |
| EBITDAEarnings before interest/tax | -$25M | -$470M | -$487M | $757M |
| Net IncomeAfter-tax profit | -$24M | -$423M | -$464M | -$185M |
| Free Cash FlowCash after capex | -$23M | -$385M | -$423M | $391M |
| Gross MarginGross profit ÷ Revenue | — | +82.1% | — | +24.9% |
| Operating MarginEBIT ÷ Revenue | — | -7.2% | — | +11.8% |
| Net MarginNet income ÷ Revenue | — | -6.4% | — | -4.6% |
| FCF MarginFCF ÷ Revenue | — | -5.8% | — | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +137.7% | — | +1.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +134.5% | -9.0% | +19.7% | -160.0% |
CRL leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
CRL leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | MBRXMoleculin Biotech… | AGIOAgios Pharmaceuti… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| Market CapShares × price | $29M | $1.6B | $5.5B | $9.0B |
| Enterprise ValueMkt cap + debt − cash | $21M | $1.6B | $4.8B | $11.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.09x | -3.87x | -9.97x | -62.52x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 16.42x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 12.98x |
| Price / SalesMarket cap ÷ Revenue | — | 30.30x | — | 2.24x |
| Price / BookPrice ÷ Book value/share | 1.97x | 1.34x | 5.83x | 2.81x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 17.31x |
CRL leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
CRL leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
CRL delivers a -5.7% return on equity — every $100 of shareholder capital generates $-6 in annual profit, vs $-3 for MBRX. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRL's 0.95x. On the Piotroski fundamental quality scale (0–9), CRL scores 4/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | MBRXMoleculin Biotech… | AGIOAgios Pharmaceuti… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -3.2% | -34.1% | -47.1% | -5.7% |
| ROA (TTM)Return on assets | -112.5% | -31.7% | -44.1% | -2.5% |
| ROICReturn on invested capital | -4.4% | -26.3% | — | +6.3% |
| ROCEReturn on capital employed | -187.1% | -33.8% | -66.1% | +8.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.05x | 0.00x | 0.95x |
| Net DebtTotal debt minus cash | -$9M | -$27M | -$714M | $2.9B |
| Cash & Equiv.Liquid assets | $9M | $89M | $714M | $214M |
| Total DebtShort + long-term debt | $222,000 | $62M | $98,000 | $3.1B |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | 6.38x |
CRL leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $496 for MBRX. Over the past 12 months, MBRX leads with a +149.2% total return vs AGIO's -2.4%. The 3-year compound annual growth rate (CAGR) favors IMVT at 12.1% vs MBRX's -40.7% — a key indicator of consistent wealth creation.
| Metric | MBRXMoleculin Biotech… | AGIOAgios Pharmaceuti… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -31.2% | +1.3% | +5.1% | -10.1% |
| 1-Year ReturnPast 12 months | +149.2% | -2.4% | +96.1% | +32.8% |
| 3-Year ReturnCumulative with dividends | -79.2% | +8.3% | +40.9% | -4.2% |
| 5-Year ReturnCumulative with dividends | -95.0% | -50.7% | +62.4% | -46.9% |
| 10-Year ReturnCumulative with dividends | -99.7% | -42.2% | +173.6% | +119.2% |
| CAGR (3Y)Annualised 3-year return | -40.7% | +2.7% | +12.1% | -1.4% |
IMVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — AGIO and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
AGIO is the less volatile stock with a 1.12 beta — it tends to amplify market swings less than CRL's 1.52 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs MBRX's 31.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MBRXMoleculin Biotech… | AGIOAgios Pharmaceuti… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 1.12x | 1.37x | 1.52x |
| 52-Week HighHighest price in past year | $7.98 | $46.00 | $30.09 | $228.88 |
| 52-Week LowLowest price in past year | $0.25 | $22.24 | $13.36 | $131.30 |
| % of 52W HighCurrent price vs 52-week peak | +31.2% | +59.8% | +90.5% | +79.5% |
| RSI (14)Momentum oscillator 0–100 | 48.5 | 41.9 | 60.2 | 57.2 |
| Avg Volume (50D)Average daily shares traded | 110K | 1.0M | 1.4M | 806K |
Evenly matched — AGIO and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MBRX as "Buy", AGIO as "Buy", IMVT as "Buy", CRL as "Buy". Consensus price targets imply 67.2% upside for IMVT (target: $46) vs 12.9% for CRL (target: $205). MBRX is the only dividend payer here at 0.35% yield — a key consideration for income-focused portfolios.
| Metric | MBRXMoleculin Biotech… | AGIOAgios Pharmaceuti… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $37.75 | $45.50 | $205.43 |
| # AnalystsCovering analysts | 4 | 29 | 23 | 36 |
| Dividend YieldAnnual dividend ÷ price | +0.4% | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | — | 1 |
| Dividend / ShareAnnual DPS | $0.01 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +4.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CRL leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). IMVT leads in 1 (Total Returns). 1 tied.
Best OverallCharles River Laboratories … (CRL)Leads 3 of 6 categories
Loading custom metrics...
MBRX vs AGIO vs IMVT vs CRL: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is MBRX or AGIO or IMVT or CRL a better buy right now?
For growth investors, Agios Pharmaceuticals, Inc.
(AGIO) is the stronger pick with 48. 0% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Analysts rate Moleculin Biotech, Inc. (MBRX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MBRX or AGIO or IMVT or CRL?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to -95. 0% for Moleculin Biotech, Inc. (MBRX). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus MBRX's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MBRX or AGIO or IMVT or CRL?
By beta (market sensitivity over 5 years), Agios Pharmaceuticals, Inc.
(AGIO) is the lower-risk stock at 1. 12β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately 36% more volatile than AGIO relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — MBRX or AGIO or IMVT or CRL?
By revenue growth (latest reported year), Agios Pharmaceuticals, Inc.
(AGIO) is pulling ahead at 48. 0% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Moleculin Biotech, Inc. grew EPS 82. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, AGIO leads at 56. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MBRX or AGIO or IMVT or CRL?
Moleculin Biotech, Inc.
(MBRX) is the more profitable company, earning 0. 0% net margin versus -764. 0% for Agios Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRL leads at 12. 6% versus -873. 9% for AGIO. At the gross margin level — before operating expenses — AGIO leads at 78. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is MBRX or AGIO or IMVT or CRL more undervalued right now?
Analyst consensus price targets imply the most upside for IMVT: 67.
2% to $45. 50.
07Which pays a better dividend — MBRX or AGIO or IMVT or CRL?
In this comparison, MBRX (0.
4% yield) pays a dividend. AGIO, IMVT, CRL do not pay a meaningful dividend and should not be held primarily for income.
08Is MBRX or AGIO or IMVT or CRL better for a retirement portfolio?
For long-horizon retirement investors, Agios Pharmaceuticals, Inc.
(AGIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 12)). Charles River Laboratories International, Inc. (CRL) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AGIO: -42. 2%, CRL: +119. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between MBRX and AGIO and IMVT and CRL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MBRX is a small-cap quality compounder stock; AGIO is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; CRL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.